Register
Login:
Share:
Email Facebook Twitter

Market analyst Rajan Dhall talks about the financial market Watch here

Market analyst Rajan Dhall talks about the financial market


Immupharma Share Chat (IMM)



Share Price: 51.75Bid: 51.00Ask: 52.50Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.50Spread as %: 2.94%Open: 52.25High: 52.50Low: 51.00Yesterday’s Close: 51.75


Share Discussion for Immupharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


boomorbust
Posts: 8,861
Off Topic
Opinion:No Opinion
Price:52.375
RE: 2014 RNS - "Potential Partner"
Sun 13:05
Think he was referring to the partnership with Simbec-Orion. The RNS is dated October 2014 and states:-

"Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical trials. Before these initial activities are completed, it is expected that a further agreement to develop Lupuzor™ will be finalised and signed which will see Immupharma and the potential partner fund the phase III trials. This agreement will also allow the partner to run the phase III pivotal programme"

Then in January 2015 they announced the collaboration with Simbec-Orion.
 
leas
Posts: 3,735
Off Topic
Opinion:No Opinion
Price:52.375
RE: 2014 RNS - "Potential Partner"
Sun 12:06
Hi Rocky, I think the company was exploring their options on how to take Lupuzor into p3 trials. At the time they did not have the funding but employed the services of Torreya to negotiate on their behalf. Thankfully that did not happen.
Make no mistake, IMM have a strong hand here and so far they do not give the impression that they are 'going to give away any rights' on the cheap.
All of course depends on a successful trial, but remembering that there are other compounds in development.
Rocky88
Posts: 4
Off Topic
Opinion:No Opinion
Price:52.375
2014 RNS - "Potential Partner"
Sun 00:50
Reading back to 2014 I find there was reference to a potential partner...

"Dr Robert Zimmer, ImmuPharma's President and Chief Scientific Officer, further commented: "The entry of Lupuzor™ into pivotal Phase III trials involves a potential partner with strong credentials and expertise in late stage clinical development. Furthermore they provide an independent validation of Lupuzor's™ potential to become a leading treatment for lupus patients world-wide"

Does anyone know who this potential partner is? Or if anything ever came of it?

I personally did not know that they were conducting the phase 3 trial with a potential partner. V interesting.
westie50
Posts: 2,158
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:51.875
RE: A reminder of the potential her..
Thu 19:20
Excellent post oilbagger. Reminds us all why we're here. Long term hold I think. Nothing is going to happen quickly. I'm looking at next year personally.
oilbagger
Posts: 71
Research
Opinion:Strong Buy
Price:52.00
A reminder of the potential here
20 Jun '17
I had another play of this old video from June 2016 of Sylvaine Muller that highlights the potential of the drug platform that Lupuzor is based. The potential is enormous so worth looking at again to remind yourself of the potential here beyond the treatment of Lupus

Sylvaine Muller, creator of ImmuPharma PLC’s (LON:IMM) lead drug candidate Lupuzor, tells Proactive Investors the treatment is “unique” in its treatment for auto-immune disease lupus, as it only targets only the autoimmune system, and not the immune system.
But, she adds, “we think that we can open up the indications in which the peptide [molecule] could be effective”.
“We have already started some experiments,” Mulller says, which will target a range of diseases including inflammatory, chronic, those related to autoimmunity and those that aren’t - like asthma.
“We have first indication that are extremely promising also in these indications,” she adds.
oilbagger
Posts: 71
Observation
Opinion:Strong Buy
Price:52.00
spread is tight
20 Jun '17
The spread is tight at the minute 52.36 to buy and can sell 50k share in at 52.125p
Looks like they are keen to mop up any shares - they aren't having mine !!
Happy to wait.
hunkymonkey
Posts: 2,706
Off Topic
Opinion:No Opinion
Price:52.25
RE: New Poster
19 Jun '17
Great find as always boom - many thanks. Halfbutt, absolutely bizarre statement, if you've been in for yrs - then obvs since phase 2 trials. Only 6 months until they complete, pharma is notorious for taking A LONG time. Strange complaint, anyways good luck with whatever you decide
JohnLaw
Posts: 409
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:52.25
RE: New Poster
19 Jun '17
I think your nick is only 50% correct halfbutt
boomorbust
Posts: 8,861
Off Topic
Opinion:No Opinion
Price:50.75
Lupuzor & autophagy
19 Jun '17
Following on from discussions over on ADVFN about Lupuzor as a platform, the abstract below from Sylviane Muller has recently been published. Previously she had further defined the mechanism of action for Lupuzor by demonstrating that it targets chaperone-mediated autophagy. The link below shows that she continues apace with research into autophagy and in particular neuronal autophagy and the role it may play in 'some inflammatory diseases of central and peripheral nervous systems'.

"Based on our own studies centred on a peptide called P140 that targets autophagy, we highlight the validity of autophagy processes, and in particular of chaperone-mediated autophagy, as a particularly pertinent pathway for developing novel selective therapeutic approaches for treating some neuronal diseases. Our findings with the P140 peptide support a direct cross-talk between autophagy and certain central and peripheral neuronal diseases."

I believe that examples of neuroinflammatory diseases are Alzheimer's, Parkinsons and MS. I haven't been able to download the full research paper (without paying), nevertheless it shows that whilst all appears to be quiet there's plenty going on in the CNRS labs.

https://www.ncbi.nlm.nih.gov/pubmed/28572049
PinWiz
Posts: 41
Off Topic
Opinion:No Opinion
Price:50.00
Interesting points
19 Jun '17
being made on the other BB, slow and steady so far today...GLA




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.